Suzan S Gad¹, Hassan A Shora²*, Amina Abdelwahab¹, Rania M Abdou⁴, Batoul M Abdel Raouf⁴, Hani A Elmikaty³, Sanaa Nassar¹, Ahmed A Ali¹, Hussein M Ismail⁶ and Ismail Dahshan⁵

¹Professor of Pediatrics, Faculty of Medicine, Suez Canal University, Egypt
²Senior Research Scientist, Harvard Medical School Associate, Port-Said University and Ismailia Medical Complex, Egypt
³Researcher of Pediatrics, National Research Centre, Egypt
⁴Lecturer of Child Psyciatry, Ain Shams university, Egypt
⁵Lecturer Family Medicine, Faculty of Medicine, Suez Canal University, Egypt
⁶Lecturer of Cardiology Faculty of Medicine, Suez Canal University, Egypt

*Corresponding Author: Hassan A Shora, Senior Research Scientist, Harvard Medical School Associate, Port-Said University and Ismailia Medical Complex, Egypt.

Received: May 02, 2022; Published: June 08, 2022

Abstract

Background and Objectives: Metabolic syndrome (MetS), one of the most serious global health issues, is considered chronic inflammatory states. Chemerin, Il-18 and Il-1 beta adipocytokines, plays an important role in linking Met S and inflammation. Few studies are conducted in Egypt to disclose the role of chemerin, Il-18 and Il-1 beta as combined biomarkers to increase its diagnostic accuracy. So the aim of our study was to evaluate the role of serum chemerin Il-18 and Il-1 beta as combined biomarkers for early detection of metabolic syndrome due to different genetic and environmental backgrounds.

Methods: The study enrolled 171 participants divided into three groups, 57 children in each group. Group I:, 57 healthy control children group II obese children without metabolic syndrome and obese children with metabolic syndrome in Group 3 and. ranging in age from 5 to 17, were included in the study. Anthropometric and blood pressure measurements were taken of the participants. Fasting blood glucose, serum triglycerides (TG), total cholesterol, high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were measured. ELISA was used to assess the amounts of circulating chemerin.

Results: Met S requirements were satisfied by 57 individuals. Abdominal obesity was the most common Met S predictor (84.2%), followed by impaired fasting blood sugar (73.7%), and then each of high triglyceride and low HDL (68.4%). Serum chemerin levels were significantly higher in Met S than in non-Met S obese and healthy subjects (1211.7 ± 1569 ng/ml VS 337.5 ± 34.8 ng/ml and 470.3 ± 475.8 ng/ml respectively, p ˂ 0.001). Serum chemerin levels were shown to be substantially linked with impaired fasting blood sugar (r = 0.398, p = 0.009) and low HDL (r = -0.386, p = 0.012) by correlation and multiple linear regression analysis.

Conclusion: Circulating chemerin Il-18 and Il-1 beta , levels were associated with metabolic syndrome and could be independent markers for this disorder.

Keywords: Children; Metabolic Syndrome; Chemerin; Il-18; Il-1 Beta; Biomarker; Obesity

References

1. Meneguetti B T., et al. “Neuropeptide receptors as potential pharmacological targets for obesity”. Pharmacology and Therapeutics 196 (2019): 59-78.
2. Hamilton D., et al. “The lifetime costs of overweight and obesity in childhood and adolescence: a systematic review”. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity4 (2018): 452-463.
3. “Childhood overweight and obesity” (2019).
4. Kumar S and Kelly A S. “Review of Childhood Obesity: From Epidemiology, Etiology, and Comorbidities to Clinical Assessment and Treatment”. Mayo Clinic proceedings2 (2017): 251-265.
5. Fornari E and Maffeis C. “Treatment of Metabolic Syndrome in Children”. Frontiers in Endocrinology 10 (2019): 702.
6. Alberti KG., et al. “Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention”. National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2018): 1640-1645.
7. Helfer G and Wu QF. “Chemerin: a multifaceted adipokine involved in metabolic disorders”. The Journal of Endocrinology 2 (2018): R79-R94.
8. Buechler C., et al. “Chemerin Isoforms and Activity in Obesity”. International Journal of Molecular Sciences,5 (2019): 1128.
9. Sledzińska M., et al. “Serum chemerin in children with excess body weight may be associated with ongoing metabolic complications - A pilot study”. Advances in Medical Sciences 2 (2017): 383- 386.
10. Niklowitz P., et al. “Link between chemerin, central obesity, and parameters of the Metabolic Syndrome: findings from a longitudinal study in obese children participating in a lifestyle intervention”. International Journal of Obesity10 (2005): 1743-1752.
11. Fontes VS., et al. “Chemerin and factors related to cardiovascular risk in children and adolescents: a systematic review. quemerina e fatores relacionados ao risco cardiovascular em crianças e adolescentes: UMA REVISÃO SISTEMÁTICA”. Revista Paulista De Pediatria: Orgao Oficial da Sociedade de Pediatria de Sao Paulo2 (2018): 221-229.
12. Ba HJ., et al. “Serum Chemerin Levels Correlate With Determinants of Metabolic Syndrome in Obese Children and Adolescents”. Clinical Medicine Insights Pediatrics 13 (2019): 1179556519853780.
13. Lalkhen AG and McCluskey A. “Clinical tests: sensitivity and specificity”. Continuing Education in Anaesthesia Critical Care and Pain 6 (2008): 221-223.
14. Šimunović M., et al. “The Prevalence of Metabolic Syndrome and Cardiovascular Risk Factors in Obese Children and Adolescents in Dalmatia: A Hospital Based Study”. International Journal of Endocrinology (2016): 1823561.
15. Tan X., et al. “Chemerin correlates with obesity and metabolic syndrome and decreases after weight loss in children”. Endocrine Abstracts (2016).
16. Zaki ME., et al. “Metabolic syndrome components in obese Egyptian children”. Annals of Saudi Medicine6 (2012): 603-610.
17. Badri S., et al. “Prevalence of Metabolic Syndrome and Its Related Factors among Adults”. The Egyptian Journal of Hospital Medicine3 (2017): 1395-1399.
18. Badri SM., et al. “Prevalence of Metabolic Syndrome and Its Related Factors among Adults”. Egyptian Journal of Hospital Medicine3 (2017).
19. Bokor S., et al. “Prevalence of metabolic syndrome in European obese children”. International Journal of Pediatric Obesity: IJPO: An Official Journal of the International Association for the Study of Obesity 3 (2008): 3-8.
20. Dejavitte R., et al. “Prevalence of metabolic syndrome and its associated factors in overweight and obese adolescents”. Journal of Pediatric Endocrinology and Metabolism: JPEM 2 (2020): 233-239.
21. Choi D H., et al. “Usefulness of the Waist Circumference-to-Height Ratio in Screening for Obesity and Metabolic Syndrome among Korean Children and Adolescents: Korea National Health and Nutrition Examination Survey, 2010-2014”. Nutrients 3 (2017): 256.
22. Ejtahed HS., et al. “Utility of waist circumference-to-height ratio as a screening tool for generalized and central obesity among Iranian children and adolescents: The CASPIAN-V study”. Pediatric Diabetes5 (2019): 530-537.
23. Dahpy Marwa., et al. “The associations among RARRES2 rs17173608 gene polymorphism, serum chemerin, and non-traditional lipid profile in patients with metabolic syndrome”. Egyptian Journal of Medical Human Genetics (2020).
24. Ouerghi N., et al. “Association of selected adipokines with metabolic syndrome and cardio-metabolic risk factors in young males”. Cytokine 133 (2020): 155170.
25. Maghsoudi Z., et al. “The comparison of chemerin, adiponectin and lipid profile indices in obese and non-obese adolescents”. Diabetes and Metabolic Syndrome 10 (2016): S43-S46.
26. Verrijn Stuart A A., et al. “Altered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetes”. The Journal of Clinical Endocrinology and Metabolism2 (2012): 463-472.
27. Rourke JL., et al. “Towards an integrative approach to understanding the role of chemerin in human health and disease”. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity3 (2013): 245-262.
28. Stejskal D., et al. “Chemerin is an independent marker of the metabolic syndrome in a Caucasian population--a pilot study”. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 152.2 (2008): 217-221.
29. Ba HJ., et al. “Serum Chemerin Levels Correlate With Determinants of Metabolic Syndrome in Obese Children and Adolescents”. Clinical Medicine Insights Pediatrics 13 (2019): 1179556519853780.
30. Rabelo L M. “Fatores de risco para doença aterosclerótica na adolescência [Atherosclerotic risk factors in adolescence]”. Jornal de Pediatria 77 (2001): S153-S164.
31. Cook S., et al. “Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994”. Archives of Pediatrics and Adolescent Medicine 8 (2003): 821-827.
32. Zirlik A., et al. “Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study”. Arteriosclerosis, Thrombosis, and Vascular Biology 27 (2007): 2043-2049.
33. Kim JE., et al. “The Roles and Associated Mechanisms of Adipokines in Development of Metabolic Syndrome”. Molecules 27 (2022): 334.

Citation

Citation: Suzan S Gad, Hassan A Shora and Amina Abdelwahab., et al. “Chemerin, IL-18 and IL-1 Beta as Biomarkers of Metabolic Syndrome in Egyptian Obese Children”.Acta Scientific Medical Sciences 6.7 (2022): 66-77.

Copyright

Copyright: © 2022 Hassan A Shora., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.